News
The Frederick National Laboratory for Cancer Research will spearhead a national R&D initiative focused on mutations in a family of genes called Ras, which play a role in 33 percent of all human cancers, including 90 percent of pancreatic cancers.
With unanimous concurrence of both the National Cancer Advisory Board (NCAB) and the…
News
Cancer immunotherapy is a type of treatment in which the body’s own immune system is used to attack and kill cancer cells or keep them from spreading. To date, the immunotherapy agent interleukin-2 (IL-2) has been approved by the U.S. Food and Drug Administration for treating certain types of melanoma and kidney cancer.1
IL-2 therapy, however,…
News
The Molecular Characterization Laboratory at the Frederick National Laboratory for Cancer Research lies at the heart of an ambitious new approach for testing cancer drugs that will use the newest tools of precision medicine to select the best treatment for individual patients based on the genetic makeup of their tumors.
The protocol, called NCI…
News
An investigational brain cancer drug made with disabled polio virus and manufactured at the Frederick National Lab has won breakthrough status from the Food and Drug Administration (FDA) to fast-track its further refinement and clinical testing.
Breakthrough status is designed to speed the development and approval of candidate therapies that…
News
The U.S. Food and Drug Administration (FDA) has approved dinutuximab (ch14.18) as an immunotherapy for neuroblastoma, a rare type of childhood cancer that offers poor prognosis for about half of the children who are affected.
The National Cancer Institute’s (NCI) Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory…
